Home Featured Page 201

Featured

Latest

Dylan Beynon – Mindbloom – At Home Ketamine

Beckley’s 5-MeO-DMT Shows Rapid, Durable Antidepressant Effects in Phase 2b Study

Beckley Execs Talk Phase 2b Data, Competition, and Phase 3 Plans

Beckley and atai Leadership Unpack Phase 2b Data, Take Aim at GH’s Dosing Model

Beyond the Endpoint: Industry Voices Reflect on Compass’ Phase 3 Readout

Silo Pharma Enters into Sponsored Research Agreement with Columbia University to...

Nova Mentis Earns Psilocybin Orphan Drug Designation in Europe for Fragile...

MINDCURE Announces Financial Results for the First Quarter of Fiscal 2022

Cybin Announces FDA Investigational New Drug Authorization of Cybin’s Sponsored Feasibility...

PT268 – Hamilton Morris – PCP, 5-MeO-DMT, and The Synthesis of...

MindMed Expands its Drug Development Pipeline with Launch of R(-)-MDMA Program

HAVN Life Announces Departure of Rick Brar as Director

Delix Therapeutics Announces Appointment of Dr. John Krystal to Scientific &...

European Patent Grant Strengthens Small Pharma’s Ketamine-Based Patent Portfolio for the...

MindMed CMO to Chair Digital Biomarkers Summit

1...200201202...291 Page 201 of 291

Dylan Beynon – Mindbloom – At Home Ketamine

Beckley’s 5-MeO-DMT Shows Rapid, Durable Antidepressant Effects in Phase 2b Study

Beckley Execs Talk Phase 2b Data, Competition, and Phase 3 Plans

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Dylan Beynon – Mindbloom – At Home Ketamine

Beckley’s 5-MeO-DMT Shows Rapid, Durable Antidepressant Effects in Phase 2b Study

Beckley Execs Talk Phase 2b Data, Competition, and Phase 3 Plans

Beckley and atai Leadership Unpack Phase 2b Data, Take Aim at GH’s Dosing Model

Beyond the Endpoint: Industry Voices Reflect on Compass’ Phase 3 Readout

Silo Pharma Enters into Sponsored Research Agreement with Columbia University to...

Nova Mentis Earns Psilocybin Orphan Drug Designation in Europe for Fragile...

MINDCURE Announces Financial Results for the First Quarter of Fiscal 2022

Cybin Announces FDA Investigational New Drug Authorization of Cybin’s Sponsored Feasibility...

PT268 – Hamilton Morris – PCP, 5-MeO-DMT, and The Synthesis of...

MindMed Expands its Drug Development Pipeline with Launch of R(-)-MDMA Program

HAVN Life Announces Departure of Rick Brar as Director

Delix Therapeutics Announces Appointment of Dr. John Krystal to Scientific &...

European Patent Grant Strengthens Small Pharma’s Ketamine-Based Patent Portfolio for the...

MindMed CMO to Chair Digital Biomarkers Summit

EDITOR PICKS

Dylan Beynon – Mindbloom – At Home Ketamine

Beckley’s 5-MeO-DMT Shows Rapid, Durable Antidepressant Effects in Phase 2b Study

Beckley Execs Talk Phase 2b Data, Competition, and Phase 3 Plans

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY